Anti-inflammatory effects of tumour necrosis factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-beta-treated antigen-presenting cells.
Exposure of macrophages to transforming growth factor (TGF)-beta is known to alter their functional phenotype such that antigen presentation by these cells leads to tolerance rather than an inflammatory immune response. Typically, eye-derived antigen-presenting cells (APCs) exposed to TGF-beta in the local environment are known to induce a form of peripheral tolerance and protect the eye from inflammatory immune effector-mediated damage. In response to TGF-beta, APCs increase their expression of tumour necrosis factor (TNF)-alpha and TNF receptor 2 (TNF-R2). Although TNF-alpha has been implicated in tolerance and the associated regulation of the inflammatory immune response, its source and the receptors involved remain unclear. In this report we determined the contribution of TNF-alpha and TNF-R2 expressed by TGF-beta-treated APCs to their anti-inflammatory tolerogenic effect. Our results indicate that APC-derived TNF-alpha is essential for the ability of APCs to regulate the immune response and their IL-12 secretion. Moreover, in the absence of TNF-R2, APCs exposed to TGF-beta failed to induce tolerance or regulatory cells known to participate in this tolerance. Also, blocking of TNF-R1 signalling enhanced the ability of the APCs to secrete increased TGF-beta in response to TGF-beta exposure. Together our results support an anti-inflammatory role of TNF-alpha in regulation of an immune response by TGF-beta-treated APCs and suggest that TNF-R2 contributes significantly to this role.
Masli
Sharmila
S
Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. sharmila.masli@schepens.harvard.edu
Turpie
Bruce
B
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000276:immunology*; D000938:Antigen-Presenting Cells / Q000276:immunology*; D002478:Cells, Cultured; D018920:Coculture Techniques; D007108:Immune Tolerance / Q000276:immunology; D016130:Immunophenotyping; D018664:Interleukin-12 / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000172:deficiency / Q000276:immunology*; D016212:Transforming Growth Factor beta / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000893:Anti-Inflammatory Agents; D047889:Receptors, Tumor Necrosis Factor, Type II; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13806-11
9811882
Ann N Y Acad Sci. 1998 Nov 17;859:290-4
9928407
Cell. 1995 Dec 1;83(5):793-802
8521496
FEBS Lett. 2002 Mar 27;515(1-3):119-26
11943206
J Exp Med. 2001 Feb 19;193(4):427-34
11181695
Eur J Immunol. 1997 Jul;27(7):1648-56
9247573
J Immunol. 1998 Jan 15;160(2):943-52
9551933
J Neurosci Res. 1996 Aug 15;45(4):322-33
8872892
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1803-11
10845601
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8093-8
9223320
J Immunol. 1997 Dec 15;159(12):6276-82
9550432
Biochem J. 2001 Nov 1;359(Pt 3):525-35
11672426
Eur J Immunol. 1992 Jan;22(1):165-73
1530916
Nature. 1995 Sep 28;377(6547):348-51
7566090
Nature. 1997 Feb 20;385(6618):729-33
9034190
Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9292-6
1718003
Clin Infect Dis. 2005 Aug 1;41 Suppl 3:S199-203
15983900
J Immunol. 2000 Feb 15;164(4):1722-9
10657616
J Immunol. 1998 Feb 15;160(4):1589-97
9469414
J Immunol. 2004 Feb 15;172(4):1991-5
14764660
J Immunol. 1993 Nov 1;151(9):4637-41
8409424
J Cell Sci. 2002 Jul 1;115(Pt 13):2757-70
12077366
Int Immunol. 2006 May;18(5):689-99
16569680
J Immunol. 1995 Nov 15;155(10):4661-8
7594465
Biochem Pharmacol. 2001 Mar 15;61(6):749-59
11266661
J Immunol. 1996 Sep 15;157(6):2348-57
8805632
Trends Cell Biol. 1995 Oct;5(10):392-9
14732063
Exp Dermatol. 1999 Dec;8(6):495-500
10597139
Eur J Immunol. 1999 Feb;29(2):626-32
10064079
J Immunol. 2002 Mar 1;168(5):2264-73
11859114
Br J Rheumatol. 1992 May;31(5):293-8
1581770
J Rheumatol. 2003 Oct;30(10):2287-91
14528531
J Exp Med. 1997 Oct 6;186(7):1119-28
9314560
J Immunol. 1992 Sep 1;149(5):1531-8
1387141
J Immunol. 2001 May 1;166(9):5619-28
11313402
Invest Ophthalmol Vis Sci. 2000 May;41(6):1410-21
10798657
Am J Pathol. 1999 May;154(5):1417-22
10329594
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):570-5
9435233
J Biol Chem. 1998 Aug 28;273(35):22800-6
9712914
J Immunol. 2005 Nov 15;175(10):6286-93
16272279
Invest Ophthalmol Vis Sci. 1994 Apr;35(5):2643-51
8163352
Cytokine. 2006 Feb 21;33(4):231-7
16542849
Immunology. 1999 Mar;96(3):372-80
10233718
J Immunol. 2006 Aug 1;177(3):1618-27
16849470
J Exp Med. 1995 Feb 1;181(2):607-17
7836916
J Clin Invest. 2001 Jun;107(12):1507-8
11413157